Healthy Clinical Trial
Official title:
Impact of Single Exercise Session Conducted Prior to Phenylketonuria (PKU) Type Meal on Appetite Hormones, Metabolic Rate, Fat Oxidation and Energy Intake
The study applied a randomized, crossover design with preliminary (screening) session and two sequenced experimental trials. Trials were marked as Control trial and Exercise trial. Participants were asked to either resting (Control trial) or exercising (Exercise trial) for one hour. In the two trials, appetite questionnaires were obtained, blood samples were collected, and metabolic rates were measured every 30 minutes. Participants in both trials were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal at 300 min. Participants required to record their EI for the remainder of the experimental day using a self-recorded food diary. Two days prior the experimental trials participants refrained from exercise and alcohol intake. All data collection took place in the metabolic research unit at New Lister Building, Glasgow Royal Infirmary.
Participants of the study were essentially healthy men with body mass index (BMI) ≤29 kg/m2
and aged between 22-35 years, recruited by advertisements and word of mouth. Study
participants were required to be non-smokers, to have stable body weight for one month prior
to study enrolment, and were not taking any medication, nutritional supplement or being on a
special diet. Exclusion criteria included chronic illness, eating disorder and history of
gastrointestinal operations which could interfere with the results of the study. Written
informed consent were obtained prior commencing the study. The Ethics Committee of the
collage of Medical Veterinary and Life Sciences, Glasgow University approved the study.
Preliminary session
Before joining the study, preliminary session was conducted for ~3 hours. Participants were
informed to come to the metabolic research unit at New Lister Building, Glasgow Royal
Infirmary to completed physical activity readiness questionnaire (PARQ), healthy screening
questionnaire and International physical activity questionnaire. Only participants at light
or moderate of physical activity level, answered "no" to all questions in PARQ and were in
generally good health were eligible to complete the preliminary session. Subsequently, height
and body mass were measured and a ~30 min submaximal exercise test was conducted at gradually
increasing inclines. After 4 minutes of warming up period (3.5 km/hr and 0% incline),
participants were walking at a constant speed of 6 km/hr with incline being increased by 2%
every 4 min. The test was terminated when the heart rate (HR) reached 85% of maximal HR
(HRmax) defined as 220 - age in years. During the test, participants were wearing a HR
monitor and a face mask (to measure rate of oxygen consumption (V̇O2) and rate of carbon
dioxide production (V̇CO2)). The HR monitor and the mask were both connected to the indirect
calorimetry machine (Quark RMR®, COSMED, Italy). The obtained data was used to predict
maximal oxygen consumption (V̇O2max) which was achieved by extrapolation of the HR against
V̇O2 in order to calculate workload corresponds to 60% of V̇O2max.
Experimental trials
A randomisation scheme was generated using GraphPad Software 2018© to allocate participants
to the experimental trials. Trials were marked as Control and Exercise by the researcher.
Each participant started first trial according to allocated trial randomization. On the
morning of each experiment trial, participants reported to the metabolic research unit
between 08:00 and 09:00 after an overnight fast. Height, body mass and resting metabolic rate
(RMR) were measured. A cannula was introduced into an antecubital vein and after an interval
of 10 min, a baseline blood sample was obtained. Subsequently, an appetite questionnaire was
completed. Participants were then asked to either resting (Control trial) or exercising
(Exercise trial) for one hour. The Exercise trials were conducted under controlled laboratory
conditions. Participants were exercising on the treadmill (Trackmaster Treadmills, Full
Vision, Inc., Kansas, USA) at speed and grade corresponding to 60% of their V̇O2max.
Participants were wearing a HR monitor and a face mask while exercising, connected to
indirect calorimetry equipment (Quark RMR®, COSMED, Italy). V̇O2 and V̇CO2 in the inspired
and expired air were measured to calculate fat and CHO oxidation and rate of physical
activity energy expenditure (PAEE) by using indirect calorimetry equations described by Frayn
and Macdonald (1997).
Subsequently, participants in both trials were presented to a standard isocaloric PKU type
meal at 120 min. PKU meals in Exercise and Control trials were matched for weight content and
macronutrient composition. Participants were asked to consume the entire meal within 20 min.
Appetite questionnaires were obtained and blood samples were collected at 30, 60, 90 and 120
pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min
after each blood sample. After the completion of the last measurement, the participants were
presented with an ad libitum buffet test meal which used to assess, under laboratory
conditions, the spontaneous macronutrient and energy intake (EI). After completion of each
trial, participants required to record their EI for the remainder of the experimental day
using a self-recorded food diary. Water was available throughout the trials, but intake was
replicated in the second trial and consumption time was matched. During the two days before
the first trial, participants weighed and recorded all foods and drinks consumed and were
asked to replicate this intake during the two days preceding the second trial.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |